S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Is Frontline's 20% Dividend Too Good To Be True?
Stock market today: World stocks mixed as Wall St inches toward bull market
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Wheat prices jump following collapse of major dam in southern Ukraine
Here’s What’s Driving the Price of Carvana Higher
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Tesla: How and Why It Gets To $300
It Is Not Too Late To “Git” On Board With GitLab 
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Is Frontline's 20% Dividend Too Good To Be True?
Stock market today: World stocks mixed as Wall St inches toward bull market
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Wheat prices jump following collapse of major dam in southern Ukraine
Here’s What’s Driving the Price of Carvana Higher
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Tesla: How and Why It Gets To $300
It Is Not Too Late To “Git” On Board With GitLab 
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Is Frontline's 20% Dividend Too Good To Be True?
Stock market today: World stocks mixed as Wall St inches toward bull market
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Wheat prices jump following collapse of major dam in southern Ukraine
Here’s What’s Driving the Price of Carvana Higher
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Tesla: How and Why It Gets To $300
It Is Not Too Late To “Git” On Board With GitLab 
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Is Frontline's 20% Dividend Too Good To Be True?
Stock market today: World stocks mixed as Wall St inches toward bull market
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Wheat prices jump following collapse of major dam in southern Ukraine
Here’s What’s Driving the Price of Carvana Higher
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Tesla: How and Why It Gets To $300
It Is Not Too Late To “Git” On Board With GitLab 
OTCMKTS:SHTDF

Sinopharm Group (SHTDF) Stock Forecast, Price & News

$3.46
0.00 (0.00%)
(As of 06/6/2023 ET)
Compare
Today's Range
$3.46
▼
$3.46
50-Day Range
$2.90
▼
$3.63
52-Week Range
$1.80
▼
$3.63
Volume
N/A
Average Volume
10,150 shs
Market Capitalization
N/A
P/E Ratio
3.47
Dividend Yield
7.51%
Price Target
N/A
ProfileChartCompetitorsFinancialsHeadlinesShort Interest

SHTDF stock logo

About Sinopharm Group (OTCMKTS:SHTDF) Stock

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.

Receive SHTDF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sinopharm Group and its competitors with MarketBeat's FREE daily newsletter.

SHTDF Stock News Headlines

May 12, 2023 | msn.com
Sinopharm Group (HKEX:1099) Price Target Increased by 8.31% to 29.48
April 13, 2023 | finance.yahoo.com
Pfizer signs strategic cooperation pact with China's Sinopharm
June 7, 2023 | Edge On The Street (Ad)
The $193 Billion US-China War You Don't Know About
They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.
April 6, 2023 | msn.com
WHO chief expects COVID emergency to end this year
March 24, 2023 | msn.com
China approves its first mRNA Covid-19 vaccine
March 22, 2023 | news.yahoo.com
China approves first home-grown mRNA Covid vaccine
February 23, 2023 | forbes.com
Sinopharm Group
January 20, 2023 | news.yahoo.com
Sinopharm unit gets OK for clinical trials of mRNA COVID vaccine
June 7, 2023 | Edge On The Street (Ad)
Nevada Desert more Valuable than Wall Street or Silicon Valley?
It could be true, according to Nevada Governor Steve Sisolak. The state's desert flats contain more lithium than any other geography in the world. And with electric vehicles driving a global boom in demand for lithium-ion batteries, Nevada should be on every investor's radar.
January 20, 2023 | msn.com
Pharma major Sinopharm gets approval for clinical trials of mRNA Covid-19 vaccine
December 8, 2022 | reuters.com
Sinopharm's second Chinese herb shot is potent
December 2, 2022 | seekingalpha.com
Vaxxinity says COVID vaccine outperformed Astra and Sinopharm shots as booster
September 28, 2022 | seekingalpha.com
Merck in pact with Sinopharm to launch oral COVID-19 therapy in China
September 15, 2022 | msn.com
Sinopharm to boost local COVID vaccine production in Africa
September 7, 2022 | msn.com
China’s Sinovac to test Omicron-targeting vaccines in Chile
July 27, 2022 | msn.com
Daesang to set up joint venture with China Sinopharm International
July 17, 2022 | seekingalpha.com
Week In Review: Qiming Closes $3.2 Billion For China Healthcare And Technology Investments
July 4, 2022 | msn.com
Hong Kong could have 3 Omicron-targeting jabs by end of year, as health expert reveals Sinopharm hopes to make new vaccine available by December
June 27, 2022 | msn.com
China Donates 10 Mil Doses of Sinopharm COVID-19 Vaccines, Syringes
June 22, 2022 | usnews.com
Some Omicron Sub-Variants Escaping Antibodies From Sinopharm Shot -Chinese Study
June 21, 2022 | reuters.com
Some Omicron sub-variants escaping antibodies from Sinopharm shot - Chinese study
May 31, 2022 | msn.com
University of Hong Kong, Sinopharm launch city’s first trial for Omicron-targeting vaccine which could be ready in November
May 28, 2022 | seekingalpha.com
CanSino's Covid Vaccine Gets WHO Nod. But Is It Too Little, Too Late?
April 18, 2022 | seekingalpha.com
Sinovac Biotech's Omicron-specific vaccine cleared for clinical trial in Hong Kong
April 16, 2022 | msn.com
Sinopharm, Sinovac vaccine candidates for Omicron variant gets clearance for clinical trial
April 3, 2022 | bloomberg.com
Sinopharm Says Second-Generation Vaccine Approved for Trial
February 22, 2022 | reuters.com
Antibody triggered by Sinopharm COVID booster wanes after six months - study
See More Headlines

SHTDF Price History

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Medical Distributors
Sub-Industry
N/A
Sector
Distribution Services
Current Symbol
OTCMKTS:SHTDF
CUSIP
N/A
CIK
1556605
Web
ir.sinopharmgroup.com.cn
Phone
N/A
Fax
N/A
Employees
113,234
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
3.47
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Qingming Yu (Age 59)
    Exec. Chairman
    Comp: $964.3k
  • Mr. Yong Liu (Age 54)
    Pres & Exec. Director
    Comp: $963k
  • Mr. Xiuchang Jiang (Age 59)
    CFO & VP
  • Ms. Xiaojuan Li (Age 47)
    Chief Financial Officer
  • Mr. Yijian Wu (Age 53)
    Sec. to the Board, Company Sec. & Authorised Representative
  • Mr. Wanyong Lian (Age 52)
    VP
  • Mr. Shuangjun Xu (Age 54)
    Non-Exec. VP
  • Mr. Maisong Cai (Age 53)
    VP

Key Competitors

View All Competitors













SHTDF Stock - Frequently Asked Questions

How have SHTDF shares performed in 2023?

Sinopharm Group's stock was trading at $2.53 at the start of the year. Since then, SHTDF shares have increased by 36.8% and is now trading at $3.46.
View the best growth stocks for 2023 here.

Is Sinopharm Group a good dividend stock?

Sinopharm Group (OTCMKTS:SHTDF) pays an annual dividend of $0.26 per share and currently has a dividend yield of 1.11%. The dividend payout ratio is 26.05%. This payout ratio is at a healthy, sustainable level, below 75%.

What is Sinopharm Group's stock symbol?

Sinopharm Group trades on the OTCMKTS under the ticker symbol "SHTDF."

How do I buy shares of Sinopharm Group?

Shares of SHTDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sinopharm Group's stock price today?

One share of SHTDF stock can currently be purchased for approximately $3.46.

How many employees does Sinopharm Group have?

The company employs 113,234 workers across the globe.

This page (OTCMKTS:SHTDF) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -